Compare CCK & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCK | PRAX |
|---|---|---|
| Founded | 1906 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3B | 9.6B |
| IPO Year | 2003 | 2020 |
| Metric | CCK | PRAX |
|---|---|---|
| Price | $112.86 | $322.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 15 |
| Target Price | $123.27 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 1.2M | 371.8K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ 79.72 | N/A |
| EPS | ★ 6.38 | N/A |
| Revenue | ★ $11,665,000,000.00 | N/A |
| Revenue This Year | $5.03 | N/A |
| Revenue Next Year | $2.53 | $1,840.20 |
| P/E Ratio | $18.21 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $75.98 | $26.70 |
| 52 Week High | $116.62 | $354.87 |
| Indicator | CCK | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 54.28 | 50.06 |
| Support Level | $94.24 | $290.36 |
| Resistance Level | $116.24 | $322.32 |
| Average True Range (ATR) | 2.57 | 19.02 |
| MACD | -0.21 | -2.10 |
| Stochastic Oscillator | 45.66 | 46.86 |
Crown Holdings is one of the world's largest producers of metal packaging. The company manufactures beverage cans, metal food cans, and closures as well as aerosol cans. With the purchase of Signode, the company also has a presence in a wide variety of protective transport packaging. Although it's headquartered in the United States, the vast majority of Crown's sales come from its operations in Europe, South America, and Southeast Asia.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.